? As one of the original CCOPs, the Columbus Community Clinical Oncology Program has from its initial funding in 1983 played a major role in the delivery of state-of-the-art cancer care in our communities. This means that all of our investigators and nurses are firmly committed to the concept that cancer therapy and clinical trials are mutually supportive. We believe that a clinical trial is often the best, and sometimes the only treatment option available for patients with cancer. The Columbus CCOP fulfills the goal of the CCOP program by providing the best scientific trials, extensive educational opportunities, and a framework for multi-specialty collaboration throughout central and southeastern Ohio. Continued growth has occurred over the last 5 years and our consortium is now up to 15 hospitals, and 81 physicians covering 35 counties in parts of 4 states. As we strive to reduce cancer mortality and morbidity in our community, the critical importance of participation in cancer control and prevention studies has become a major priority of our CCOP. Accrual has increased and the scope of cancer control activities has broadened as new strategies have been designed to enroll and retain patients and healthy subjects, data is acquired and submitted on an increasingly efficient basis, and the results of seminal trials are disseminated to community health professionals. Our goals are to increase the availability of clinical trials to even more communities and physicians in central and southern Ohio. We will strive to reach more minority and underserved populations, both locally as well as in the Appalachian region of southeastern Ohio. Increased collaboration with non-oncology specialists, especially in the area of cancer control trials, is another important goal. We have set these goals because our patients will benefit. The experienced investigators, nurses and allied personnel backed by the committed institutions of the Columbus CCOP are ready to continue our success, working closely with the NCI as we continue the war on cancer. ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Whitman, Cynthia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbus Community Clinical Oncology Prg
United States
Zip Code
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32

Showing the most recent 10 out of 151 publications